Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Ribonexus Receives €2M in Deep Tech Financing from Bpifrance
Ribonexus, a biotechnology start-up developing new therapies that can overcome resistance to current targeted therapies […]
Bio-Rad Introduces Anti-Cemiplimab Antibodies
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and […]
New Research from the Caris Precision Oncology Alliance Finds Prognostic and Predictive Drug-Induced Gene Signatures for Colorectal Cancer Patients
Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering […]
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that it has entered into […]
CellCentric Strengthens Leadership Team
CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, […]
Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, […]
Accord BioPharma Announces U.S. Launch for CAMCEVI™ (Leuprolide) Injection Emulsion for the Treatment of Advanced Prostate Cancer in Adults
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, […]
JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma
JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell […]
Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and […]
BioVaxys Expands Cancer Vaccine Platform
BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today the expansion of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more